Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qianlie Biertong is a Traditional Chinese Medicine (TCM) suppository developed by Heilongjiang Jiren Pharmaceutical for the treatment of chronic non-bacterial prostatitis. It is specifically indicated for patients presenting with damp-heat and blood stasis syndrome. As a rectal suppository, it is designed to deliver herbal extracts locally to the prostate to clear heat, promote diuresis, and resolve blood stasis, thereby alleviating symptoms such as pelvic pain and urinary dysfunction. The drug is currently undergoing Phase 3 clinical evaluation in China to assess its efficacy and safety in this patient population.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qianlie Biertong.